Because innate immunity and SP-A, in particular, play an important role in mitigating infection severity, we wished to investigate mechanisms in response to acute SP-A2 treatment, as this may be relevant to cases of lung infection if one were to use SP-A-regulated miRNAs or target certain genes/pathways for therapeutic purposes. The gene discussed is SFTPA1; the disease is infection.